Infigratinib
Infigratinib is in phase II clinical trials for the treatment of melanoma, recurrent glioblastoma.
Phase II clinical trials are also ongoing for the treatment of cancer with FGFR mutation, such as advanced solid malignancies with FGFR mutation, advanced or metastatic cholangiocarcinoma with FGFR genetic alterations and hematologic malignancies with FGFR genetic alterations.
General Information
Update Date：2015-08-28
- Drug Name：
- Infigratinib
- Research Code：
- BGJ-398; NVP-BGJ398
- Trade Name：
- MOA：
- FGFR kinase inhibitor
- Indication：
- Solid tumours; Melanoma; Glioblastoma multiforme; Leukemia; Cholangiocarcinoma
- Status：
- Phase II (Active)
- Company：
- Novartis (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-08-17
|
Molecular Weight | 560.48 | ||||||||||||
| Formula | C26H31Cl2N7O3 | |||||||||||||
| CAS No. | 872511-34-7 (Infigratinib); | |||||||||||||
| Chemical Name | Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-N-methyl- | |||||||||||||
| Infigratinib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||